secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116762
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea
--------------------------------------------------------------------------------

- FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.
- Net product revenues $14.6M, down 4% YoY; Qbrexza sales up 29% to $7.6M.
- Net loss $2.4M ($0.12/sh) vs net income $16.8M ($0.91/sh) in Q3 2023 (included $19M license payment).
- Adjusted EBITDA $0.3M ($0.01/sh) vs $20.8M ($1.13/sh) in Q3 2023.
- Gross margin improved to 63.9% from 57.9% due to lower inventory charges and royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/0001104659-24-116762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/tm2428053d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer